Mallinckrodt Plc (NYSE:MNK)

During the Trading Day
116.19 +1.34 / +1.17%
As of 4:03pm ET
Day’s Change
During After-Hours   Switch to standard view »
115.76 -0.431 / -0.37%
Volume: 19.6K
Health Technology
Pharmaceuticals: Other

Company Description

Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. The company operates its business through two segments: Specialty Pharmaceuticals and Global Medical Imaging. The Specialty Pharmaceuticals segment develops, manufactures and sells branded and generic drugs, including EXALGO, indicated for the treatment of moderate to severe pain in opioid-tolerant patients; and GABLOFEN, which are injections indicated for use in the management of severe spasticity of cerebral or spinal origin. The Global Medical Imaging segment develops, manufactures and markets contrast media & delivery systems and nuclear imaging agents. Its contrast media offerings include iodine-and gadolinium-containing injectable products for diagnostic imaging applications, such as computed tomography (CT) and magnetic resonance imaging (MRI) under Optiray and Optimark brands. Mallinckrodt was founded on January 9, 2013 and is headquartered in Dublin, Ireland.

Contact Information

Mallinckrodt Plc
Damastown Industrial Estate
Dublin Dublin 15
P:(531) 880-8180
Investor Relations:



Individual stakeholders7.67%
Other institutional49.52%
Mutual fund holders46.03%

Top Executives

Mark C. TrudeauPresident, Chief Executive Officer & Director
Matthew K. HarbaughChief Financial Officer & Senior Vice President
Mario SaltarelliChief Science Officer & Senior Vice President
Peter G. EdwardsSenior Vice President & General Counsel
Hugh M. OneillPresident-Specialty Pharmaceuticals & Senior VP

To view my watchlist

Not a member yet?

Sign up now for a free account